Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $3.02: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.9/10 and A.R:R 6.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 33%; Below-average business quality; Negative price momentum.
Recursion Pharmaceuticals is a clinical-stage TechBio company using an AI platform (Recursion OS) for drug discovery across biology, chemistry, and clinical development. Internal pipeline focuses on oncology and rare disease (e.g., REC-4881 in FAP, REC-617 in solid tumors).... Read more
Sell if holding. Engine safety override at $3.02: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.9/10 and A.R:R 6.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 33%; Below-average business quality; Negative price momentum. Chart setup: RSI 52 mid-range, Bollinger mid-band. Score 3.9/10, high confidence.
Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent developments
updated 2026-06-11Recent Developments — Recursion Pharmaceuticals, Inc.
Latest news
- NEWS Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5 — benzinga May 14, 2026 positive
- NEWS Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back — benzinga May 7, 2026 positive
- NEWS Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target — benzinga May 7, 2026 positive
- NEWS Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026 neutral
- NEWS Recursion Pharmaceuticals Q1 EPS $(0.22) Beats $(0.27) Estimate, Sales $6.472M Miss $15.777M Estimate — benzinga May 6, 2026 negative
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyRoche and Genentech, Takeda, and Bayer10-K Item 1A: 'operating revenue has primarily been generated through funded research and development agreements with Roche and Genentech, Takeda, and Bayer'
Material Events(8-K, last 90d)
- 2026-03-25Item 5.02MEDIUMVicki Goodman, M.D. appointed as Chief Medical Officer of Recursion effective April 6, 2026. David Mauro, M.D., Ph.D. transitions out with advisory capacity through May 29, 2026. Clean handoff with successor named.SEC filing →
- 2026-04-30Item 5.02LOWChristopher Gibson, Board Chair of Recursion, will not stand for re-election as Class II director at 2026 Annual Meeting. Decision not due to any disagreement with the Company. Routine board transition.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Volatile — 10.8% daily ATR makes tight stops impractical. Position-size conservatively.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.02: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.9/10 and A.R:R 6.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 33%; Below-average business quality; Negative price momentum. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $2.83. Score 3.9/10, high confidence.
Take-profit target: $5.78 (+90.1% upside). Prior stop was $2.83. Stop-loss: $2.83.
Concentration risk — Counterparty: Roche and Genentech, Takeda, and Bayer; Quality below floor (1.5 < 4.0); Value-trap signals (2/5): High leverage (D/E 3.6), Material insider selling (3 sells, 16.39% of cap).
Recursion Pharmaceuticals, Inc. trades at a P/E of N/A (forward -3.7). TrendMatrix value score: 5.4/10. Verdict: Sell.
14 analysts cover RXRX with a consensus score of 3.7/5. Average price target: $7.
What does Recursion Pharmaceuticals, Inc. do?Recursion Pharmaceuticals is a clinical-stage TechBio company using an AI platform (Recursion OS) for drug discovery...
Recursion Pharmaceuticals is a clinical-stage TechBio company using an AI platform (Recursion OS) for drug discovery across biology, chemistry, and clinical development. Internal pipeline focuses on oncology and rare disease (e.g., REC-4881 in FAP, REC-617 in solid tumors). Revenue primarily comes from collaborations with Roche/Genentech, Sanofi, Bayer, and Merck KGaA, totaling >$500M to date.